1. A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants. (3rd October 2022) Authors: Perera, V; Abelian, G; Luettgen, J; Aronson, R; Li, D; Wang, Z; Zhang, L; Lubin, S; Merali, S; Murthy, B Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. (15th June 2017) Authors: Catlett, I; Aras, U; Liu, Y; Bei, D; Girgis, I; Murthy, B; Honczarenko, M; Rose, S Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 859 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Single-dose pharmacokinetics of BMS-986177/JNJ-70033093 in participants with mild or moderate hepatic impairment compared to healthy participants. (25th November 2020) Authors: Perera, V; Abelian, G; Li, D; Wang, Z; Zhang, L; Lubin, S; Wang, J; Bello, A; Murthy, B Journal: European heart journal Issue: Volume 41:(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗